
News|Articles|October 2, 2025
Q3 2025 Recap: Dermatology News and Updates
Author(s)Tim Smith
Fact checked by: Abigail Brooks, MA
This review of Q3 developments in the dermatology space highlight a number of significant news stories from 2025.
Advertisement
Advertisement
As Q3 draws to a close, the HCPLive team reviews pivotal updates across the field of
Related to this article

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.

Oral icotrokinra beat placebo and was noninferior to ustekinumab in moderate to severe plaque psoriasis in the phase 3 ICONIC-ASCEND trial.

Experts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.

Leigh Ann Pansch, MSN, FNP-BC, DCNP, discusses year-round photoprotection, missed skin cancer detection, and overlooked patients for Healthy Skin Month.

Post hoc analyses at ACAAI 2026 show 41.7% of patients-maintained CSU control and quality of life 16 weeks after stopping omalizumab.

Risankizumab improved skin clearance, itch, and quality of life through 52 weeks in pediatric psoriasis in the phase 3 OptIMMize-1 study.
Advertisement
Advertisement

